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Abstract
Antiretroviral drugs that inhibit viral replication were expected to reduce transmission of HIV by
lowering the concentration of HIV in the genital tract. In 11 of 13 observational studies,
antiretroviral therapy (ART) provided to an HIV-infected index case led to greatly reduced
transmission of HIV to a sexual partner. In the HPTN 052 randomised controlled trial, ART used
in combination with condoms and counselling reduced HIV transmission by 96·4%. Evidence is
growing that wider, earlier initiation of ART could reduce population-level incidence of HIV.
However, the full benefits of this strategy will probably need universal access to very early ART
and excellent adherence to treatment. Challenges to this approach are substantial. First, not all
HIV-infected individuals can be located, especially people with acute and early infection who are
most contagious. Second, the ability of ART to prevent HIV transmission in men who have sex
with men (MSM) and people who use intravenous drugs has not been shown. Indeed, the stable or
increased incidence of HIV in MSM in some communities where widespread use of ART has been
established emphasises the concern that not enough is known about treatment as prevention for
this crucial population. Third, although US guidelines call for immediate use of ART, such
guidelines have not been embraced worldwide. Some experts do not believe that immediate or
early ART is justified by present evidence, or that health-care infrastructure for this approach is
sufficient. These concerns are very difficult to resolve. Ongoing community-based prospective
trials of early ART are likely to help to establish the population-level benefit of ART, and—if
successful—to galvanise treatment as prevention.
Introduction
Development of many antiretroviral drugs has made HIV infection a treatable chronic
disease.1 Initiation of antiretroviral therapy (ART) soon after infection offers near normal
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quality of life and lifespan.2 Early ART is also associated with a reduced latent viral
reservoir,3 reduced viral DNA,4 and normalisation of some immune markers.5
Yet HIV prevention has been a constant struggle. Although the estimated incidence of HIV
decreased by 50% in 25 countries between 2001 and 2011, 2·5 million people still became
newly infected in 2011.6 Furthermore, encouraging reductions in the global incidence of
HIV cannot be fully explained or ascribed to one intervention.
Figure 1 shows several strategies for HIV prevention. However, in the absence of a vaccine
(which will probably be the case for the foreseeable future7), combinations of intervention
strategies must be used.8,9 The combination prevention approach was put forward in the US
Government’s new national HIV/AIDS strategy,10 and in the global President’s Emergency
Plan for AIDS Relief (PEPFAR).11
Perhaps no part of combination HIV prevention has attracted more attention than the use of
antiretroviral drugs. There are three ways in which these drugs can be deployed: as
postexposure prophylaxis, as pre-exposure prophylaxis, and to reduce infectiousness of
HIV-infected people to their sexual partners (treatment as prevention). First, suspected
exposure to HIV can be followed by postexposure prophylaxis with antiretroviral
drugs.12–14 This approach has been accepted as standard policy for both occupational
exposure in health-care workers (eg, a needlestick injury)12,13 and non-occupational
exposure (eg, an unprotected sexual encounter).14 Recommendations for postexposure
prophylaxis are based on findings from experiments with macaques and an observational
study in people who have been exposed to needlesticks.15,16 Second, gel-formulated and
oral-based ART have been used successfully as pre-exposure prophylaxis for people at high
risk for HIV infection. The combination of emtricitabine and tenofovir disoproxil fumarate
(Truvada; Gilead Sciences, Foster City, CA, USA) has been approved by the US Food and
Drug Administration as pre-exposure prophylaxis for particular high-risk groups. However,
pre-exposure prophylaxis did not provide protection in all clinical trials, most likely because
of poor adherence to study drugs.17–19 In this Review, we provide a comprehensive, timely,
and critical assessment of the third use of ART, as treatment as prevention.
The HIV transmission event
The biology of HIV transmission has been best characterised in the rhesus macaque. Shortly
after mucosal exposure, several foci of nascent HIV replication can be seen.20–22 Yet both in
macaques exposed to a physiological dose of simian HIV23–25 and in people with acute
infection25,26 a very small number of HIV variants (founder viruses) cause infection. These
viruses use both CD4 and CCR5 receptors,25,27 and differ from other variants in envelope
properties such as glycosylation and susceptibility to interferon α, suggesting a selective
advantage of founder viruses for conditions at the mucosal surface.27,28
HIV transmission efficiency depends on the inoculum from the infected person, and the
susceptibility of the exposed person.29 In 2000, Quinn and colleagues30 reported no
heterosexual HIV transmission when the blood plasma viral load was less than 1500 copies
per mL, and the greatest number of transmission events when viral load was greater than 37
500 copies per mL. The highest viral loads are noted immediately after infection (referred to
as acute and early infection),4,31 and people with acute infection are probably the most
contagious.31 However, mathematical modelling suggests that infectivity plateaus above a
viral load of 80–100 000 copies of HIV RNA per mL blood plasma.32 Accordingly, the
phenotype of the founder virus might also help to establish the probability of the HIV
transmission event in addition to inoculum effects.27,28,33
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The average risk for sexual HIV transmission in a serodiscordant heterosexual couple is
approximately 0·0010–0·0019.34 However, this is probably an underestimate because
discordant couples enrolled in longitudinal observational cohort studies inevitably receive
more medical care and counselling than does a typical patient, and might generally be at
lower risk for a transmission event (ie, due to selection bias since they have remained
discordant despite past exposure).29 Additionally, inflammation in the genital tract can be
expected to increase the probability of HIV transmission greatly by increasing the inoculum
size in the HIV-infected individual and the number of receptive cells and state of cellular
activation in the HIV-negative partner.35 Circumcision reduces acquisition efficiency36 by
removing access to receptive cells in the foreskin.37 Anal intercourse with an HIV-infected
insertive partner increases transmission probability,38 presumably because rectal mucosa is
far more friable than vaginal or cervical mucosa, and is rich in cells that are susceptible to
HIV.
Antiretroviral drugs and the genital tract
ART can be expected to reduce HIV transmission by reducing the concentration of virus in
the blood and genital secretions of the person with HIV infection. Several groups have
shown the ability of ART to penetrate the male and female genital tract39,40 and the ability
of these drugs to suppress viral replication in the genital tract. Most (but not all)
antiretroviral drugs can be expected to achieve similar or higher concentrations in the genital
tract as in blood (figure 2). An important exception is among some of the protease inhibitors
and non-nucleoside reverse transcriptase inhibitors. When protease inhibitors were first
introduced, several investigators reported resistant variants in semen,41,42 most probably
because the drugs did not reach sufficient concentration in this compartment and selected for
viral resistance. A similar potential limitation for the non-nucleoside reverse transcriptase
inhibitors in the female genital tract has been suggested.43
Patterson and colleagues44 have raised a different concern. In a study of the female genital
tract and colorectum, the investigators noted that the concentrations of tenofovir and
emtricitabine and their respective active metabolites (tenofovir diphosphate and
emtricitabine triphosphate) varied according to mucosal tissue type. Tenofovir and its
metabolite concentrations were 100-times greater in rectal tissue than in vaginal or cervical
tissue, whereas emtricitabine and its metabolite concentrations were 10–15-times greater in
vaginal or cervical tissue than in rectal tissue. Differential penetration or metabolism of
antiretroviral drugs offers insight into the greatly variable level of protection conferred by
antiretroviral drugs in some clinical trials of pre-exposure prophylaxis.39 These results
suggest that selection of antiretrovirals for HIV prevention can be optimised by choosing
drugs that preferentially penetrate sites of HIV acquisition or transmission, or by choosing
those with long tissue half-life that might provide a so-called pharmacological buffer for
imperfect drug adherence.
For unknown reasons, combination ART does not eliminate recovery of HIV from the male
or female genital tract. Even when HIV replication is suppressed in the blood by ART,
copies of HIV RNA can still routinely be recovered from the male45 and female46 genital
tract, and the rectal mucosa.47 Whether copies of HIV recovered during treatment are
replication competent and capable of causing infection, or are in fact defective and
innocuous, is unclear.
Preventive use of ART
Findings from ecological studies, observational cohort studies, and one randomised control
trial have shown the ability of ART to prevent sexual HIV transmission. Investigators of
ecological studies have analysed changes in regional spread of HIV relative to use of ART
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to assess whether a policy of treatment as prevention (eg, frequent widespread testing
coupled with ART initiation at diagnosis48,49) has slowed population-level HIV
transmission. These studies take advantage of natural experiments in settings such as San
Francisco (CA, USA)50 or British Columbia (Canada),51 where existing HIV control
strategies have already achieved high testing and treatment coverage. The most encouraging
results are from KwaZulu-Natal, South Africa, where investigators used geospatial
techniques to assess the relation between ART use and HIV incidence. HIV seroconversion
was monitored over several years in an observational cohort of more than 16 000
participants living in different communities.52 After adjustment for sexual behaviour and
prevalent HIV cases, the investigators reported that each percentage point increase in ART
coverage of HIV-infected people lowered the HIV-infection risk in a community by 1·7%.
However, not all studies have reported a fall in HIV with increased availability of ART.53
Additionally, recent studies focused on MSM have not shown a population prevention
benefit from more widespread use of ART. Importantly, ecological studies have
methodological limitations,49,53 including insufficient person-level details that are needed to
establish the causal effects,54 and inability to exclude all the potential confounding factors
from biological mechanisms and behavioural risk.49,53,55 Associations inferred from
ecological observations can almost never draw definitive conclusions of causality, and this
limitation must be recognised by researchers and policy makers.
Serodiscordant couples
Findings from observational studies of serodiscordant, sexually engaged couples have
informed individual-level investigations into the protective effects of ART. By comparing
the experiences of serodiscordant couples in which infected partners were either receiving or
not receiving ART, results of these studies strengthened the hypothesis that ART could
reduce the risk of HIV transmission.56 On the basis of these results, in 2008, Swiss experts
recommended that suppressive ART, when properly used, could provide sufficient
protection to allow unprotected sexual intercourse.57 However, not every observational
study has shown transmission prevention in couples by ART.58,59
Accordingly, to better define the role of ART for prevention, the US National Institutes for
Health (NIH) supported a randomised clinical trial, HPTN 052, that was designed to
quantify the magnitude and durability of benefit of early ART initiation for prevention of
transmission in serodiscordant couples.60 The study included measurement of individual-
level clinical consequences of earlier ART.61 1763 HIV discordant couples (97%
heterosexual) were enrolled at 13 sites in nine countries. Enrolment required having a stable
sexual partnership (>3 months) that led to three or more episodes of vaginal or anal
intercourse during this time, no previous exposure to ART, and a CD4 count at enrolment
between 350 and 550 cells per µL.
Participants in the HPTN 052 study were fully enrolled by April, 2009, and the trial will
continue until mid-2015. However, in April, 2011, the trial’s independent data safety and
monitoring board asked that interim results be made public, and at that time all HIV-infected
participants were offered ART irrespective of CD4 cell count. The interim results showed
that counselling and earlier initiation of ART reduced linked HIV transmissions by 96·4%.
Linked transmissions are designated as those in which the viral sequence in the HIV-
infected index case and newly infected partner are nearly identical, and different from other
unrelated viral strains in the community.62 The results of the HPTN 052 trial also showed
individual-level clinical benefits; earlier treatment significantly reduced tuberculosis and
other less serious infections including candida and recurrent herpes zoster (shingles).61
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In view of these findings, PEPFAR,11 the US Department of Health and Human Services,63
and WHO64,65 responded by amending their respective treatment guidelines to recommend
immediate ART for people in HIV discordant relationships, irrespective of CD4 cell count.
Three systematic reviews of sexual HIV transmission in heterosexual serodiscordant couples
have shown significant reductions in transmission for people receiving ART versus those
not.66–68
Moving from evidence to application
Translation of research findings into public health practice represents an exciting prospect
but with many challenges. Efficacy shown in a randomised controlled trial might not lead to
an effective intervention in the general population. Accordingly, the population-level
benefits of treatment as prevention remain unproven. Although treatment of discordant
couples is now standard, the effects of this approach on the overall epidemic are debated for
several reasons.69,70
For example, the generalisability of results of treatment as prevention from studies of
heterosexual couples is unknown. Will treatment reduce transmission by similar magnitudes
in other high-risk heterosexual people (eg, sex workers and their clients), MSM, and
intravenous drug users? HIV transmission through unsafe injection of drugs71 or anal
sex38,72 has considerable transmission probability, which could limit the prevention benefits
of ART. Similarly, the differential concentration and metabolism of antiviral drugs in the
genital tract and rectum,39,40,44 and specific behavioural practices in high-risk groups,73
might compromise the efficacy of ART for prevention. Widespread use of ART in MSM
populations in London (UK),74 Australia,75 and the Netherlands76 has not led to reductions
in HIV incidence. This disappointing finding could have several explanations. First,
imperfect use of ART by treated men might limit the transmission prevention benefit.
Second, untreated men probably represent the source of continued spread of HIV in MSM,
and men with acute and early HIV might represent the greatest risk for spread.74,77 Third, an
increased number of HIV-infected cells and varying pharmacology of some antiretroviral
drugs in rectal tissues (figure 2) could reduce the ability of ART to prevent HIV
transmission associated with unprotected receptive anal intercourse. Similarly, vulnerable
rectal mucosa might remain susceptible to a relatively small viral inoculum during
unprotected insertive anal intercourse.74–76
Rapid ART rollout for preventive purposes raises the possibility of other substantial
negative consequences. Increased risk behaviours in MSM associated with widespread
availability of ART in some wealthier countries74,76,78,79 could presage similar patterns in
other populations. A 2004 meta-analysis (most studies included MSM) showed no
association between being on ART and increased sexual risk behaviour. Yet, beliefs about
the protective and preventive benefits of ART were significantly associated with increased
unprotected sex irrespective of HIV serostatus.79 An updated systematic review of studies
published from 2009 to 2012 reported continuity in these findings, with associations noted
between optimistic ART-related beliefs and increased risk of HIV transmission.80
Additionally, findings from some mathematical models have suggested that wider use of
ART could lead to greater drug resistance, compromising both treatment and prevention.81
To address these and other concerns, more than 50 empirical studies of treatment as
prevention are planned or ongoing.82 Several community randomised trials have already
been launched.83 PEPFAR, NIH, the US Centers for Disease Control and Prevention, and
the Bill & Melinda Gates Foundation are supporting very large-scale trials. In Zambia and
South Africa, communities participating in the HPTN 071 trial (NCT01900977) have been
randomly assigned to one of three groups so that HIV-infected people receive: standard of
Cohen et al. Page 5













care, enhanced standard of care when CD4 count falls to 350 cells per µL, or immediate
ART irrespective of CD4 count, depending on their community. In Botswana, the Mochudi
Prevention Project (NCT01583439)84 is a targeted strategy being tested in which earlier
treatment of HIV-infected patients will be directed towards those with the highest viral
loads, who are arguably most contagious. The SEARCH (Sustainable East Africa Research
in Community Health) study (NCT01864603) is designed to assess the health, economic,
and educational effects of early HIV diagnosis and immediate initiation of ART with a
streamlined care delivery system in rural communities in east Africa. The Agence Nationale
de Recherche sur le Sida (ANRS) has designed a community randomised trial of 34 clusters
in rural KwaZulu Natal; individuals in the intervention clusters will be started on ART
irrespective of CD4 cell count when untreated HIV is detected in a screening campaign.85
All these studies are expected to use combination prevention with counselling, condoms,
and treatment for sexually transmitted diseases, in addition to wider and earlier use of ART.
Modelling of the effect of ART on pandemics
Early modelling work of the effects of ART to reduce transmission led to very conservative
estimates of benefit.86 However, newer model analyses suggest that the costs and attendant
risk of expanding ART programmes will be justified by their benefits, especially in the long
term.87
There are three possible ART expansion routes.88 The first is a low-cost, low-impact
strategy of expanding treatment eligibility for those who are already attending clinic. A
medium-cost, medium-impact strategy would use resources to reach groups who could
benefit most from early initiation of ART. These groups vary between settings, but in
generalised epidemics might include people with long-term uninfected partners, infected
pregnant women, and sex workers. In concentrated epidemics, target groups might include
sex workers, intravenous drug users, and MSM. A high-cost, high-impact strategy would
launch massive outreach campaigns to connect all HIV-infected people with the clinic and
start treatment. Importantly, cost differences between the scenarios are strongly related to
the resources needed for outreach programmes, testing and linkage to care, and the cost of
ART drugs themselves. Optimised spending across the HIV continuum of care thus
represents the next frontier to control cost in response to HIV epidemics worldwide.
Despite the increasing amount of modelling evidence for a net benefit for expanded ART,
the cost–benefit equations are more uncertain than commonly acknowledged. Three main
areas of limitations in present model analyses stem from insufficient data and reliance on
credible but unproven assumptions. First, most of the presumed population-level health
benefits of expanded ART come from a reduction in HIV transmission. These gains are
calculated from a complicated set of processes determined by the network of sexual
contacts, and a set of assumptions about the biology of HIV infection and the transmission
event.87–89 Indeed, the effect of ART in reducing transmission through routes other than
heterosexual contact is not definitively known.90
Second, all model analyses must extrapolate from past performance of ART programmes to
make future projections. This approach often works well, but the use of treatment to prevent
HIV is unprecedented and data may be too scant for mathematical models to reliably and
accurately reflect all the relevant contributing factors. For example, the assumptions for the
adherence and retention of patients initiated on ART while still healthy are made from
cohorts of patients who were started on ART after having had serious disease. Furthermore,
most models have assumed that risk behaviour patterns would not change after ART
initiation aimed at reduction of transmission. If, in fact, people starting ART much earlier
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have poorer adherence91 or increased risk behaviours,73,74,76,78,92 then models will
overestimate the benefits of expanded treatment.
A closely related problem is the difficulty in estimation of the cost of a new intervention,
particularly when the new intervention differs in scale to what has come before. For
example, the costs of treating the most peripherally located HIV-infected people (both
geographically and socially) are unlikely to equal the costs of treating typical residents in
urban areas near medical facilities.93 Guides to estimate these cost increases are inadequate.
Costing models also make assumptions about how programmes adapt to changing
circumstances. For example, as programmes expand, the number of HIV-infected people not
in care will decrease, but how efficiently programmes will be able to adapt their approach to
find those remaining cases is unknown. Furthermore, cost-effectiveness research has yet to
adequately quantify estimates for the costs of staff time, new infrastructure development,
and expansion of the drug supply chain. Model analyses have used all data available to
account for these factors, but the fundamental little experience with such programmes means
that costs are a key source of uncertainty in discussions about the cost-effectiveness of
treatment expansion.
The final limitation in present model analyses is in the unknown operationalisation of
treatment as prevention. For example, how will clinics prioritise patients with CD4 counts
less than 350 cells per µL, as recommended by the new WHO guidelines?65 In settings with
low coverage of ART, implementation of new guidelines designed to start ART sooner for
HIV infection could (for many reasons) actually reduce the opportunities for treatment of
HIV-infected people with very low CD4 cell counts or more advanced disease, especially in
resource-constrained settings. The extent to which this scenario might happen is unknown,
but such an unintended consequence would be deleterious from both an equity and
epidemiological perspective. Similarly, if a programme prioritised treatment for those in
stable discordant relationships, how would such people be identified and how would the
programme define stable? Model projections will not be useful or relevant for programmes
if they have not correctly anticipated such operational issues.
Implementation challenges
The movement towards treatment as prevention has unmasked a massive gap in the strategy
—namely, the difficulty to find and treat people at greatest risk for transmission, who may
be hardest to reach. This limitation has both scientific and social underpinnings.
Scientifically, routine HIV testing will not identify people with acute infection. In view of
the potential importance of such people to the spread of HIV,31,94,95 we need to set an even
higher scientific priority on finding means to identify early infections.96 Socially, those most
likely to transmit HIV are often among the most stigmatised groups in society. Encouraging
those at most risk to seek testing, and to adhere to ART if infected, will take political will
and new resources to invest in evidence-based programmes for these marginalised key
populations.
Additionally, the challenge of the HIV treatment cascade remains a major problem.97
Almost everywhere, large gaps exist between the number of people infected, those who
know that they are infected, and those receiving reliable treatment. So-called leakage from
the various stages of the cascade leads to programme inefficiencies and missed opportunities
for both treatment and prevention. Furthermore, treatment providers can face logistical
challenges in optimisation of therapy, and provision of HIV prevention services in treatment
clinics has been difficult, whether such services are directed at infected people or their
sexual partners, or HIV-negative people at risk for infection.
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The treatment as prevention strategy also seems to be compromised by a lack of universal
agreement about when to start ART for HIV infection, whether for individual health, to
prevent HIV transmission, or for both benefits combined. Confusion among patients and
providers about when to start ART must inevitably make cascade leakage worse, because of
the de-facto message that treatment of HIV infection is not urgent. If early treatment is not
perceived to be crucial, testing and linkage to care become optional, and retention becomes
more difficult. Adakun and colleagues91 reported poor adherence to ART started at a CD4
count greater than 250 cells per µL, arguing that lack of recognised clinical benefit (since
many participants were not symptomatic at baseline) and lack of social support otherwise
available for patients with AIDS contributed to poor adherence among such individuals. At
the same time, several investigators have reported that patients who seek care and are not
offered ART have a remarkable rate of loss to follow-up.98,99
The debate about when to start ART has mixed the results of observational trials,
randomised clinical trials, expert opinion, treatment guidelines, and logistical challenges,
which makes a dispassionate evaluation of the topic confusing and difficult. Clearly, severe
and fatal complications of HIV can be expected when CD4 count falls to less than 200 cells
per µL. Findings from several observational studies,100–103 two randomised clinical trials
(CIPRA Haiti104 and HPTN 05260), and one post-hoc analysis (SMART105) suggest a
clinical benefit when ART is started between a CD4 count of 350 and 550 cells per µL.
Investigators from the COHERE cohort, following more than 200 000 people for 1 154 803
person-years, reported measurable clinical benefit when ART was started at a CD4 count as
high as 750 cells per µL, but not greater.106
On the basis of available evidence, WHO has recommended that all HIV-infected people in
a discordant relationship64,65 and HIV-infected pregnant women107 start ART immediately.
WHO now recommends that ART be started at a CD4 count of 500 cells per µL,65 and the
International AIDS Society USA108 and US Department of Health and Human Services63
recommend immediate treatment for everyone, including people with acute HIV infection.
These results notwithstanding, some experts argue that there has not been sufficient
evidence of meaningful clinical benefit to justify starting ART in asymptomatic people at
CD4 counts greater than 350 cells per µL.109 And in fact, expansion of earlier ART in
resource-constrained settings where older, more toxic regimens are still the standard of care
could pose specific ethical and clinical challenges.110,111 Additionally, valid concerns exist
about the degree of benefit of very early ART, which itself might be modest. First, although
the inflammation associated with untreated HIV is assumed to be harmful, the exact degree
to which earlier ART will reduce inflammation and the degree of resulting benefit—if any—
are unknown. Second, early ART could add additional years of treatment, and the side-
effects of ART over many years are unknown. Third, the logistical challenges of early ART
in resource-constrained settings (eg, less toxic drugs unavailable, second-line drugs
unavailable, no viral-load measurement, no resistance testing, drug stock outs) could
compromise treatment, and lead to earlier treatment failure.111,112 Fourth, ART might lead
to sexual disinhibition that might negate ART prevention benefits. Fifth, earlier initiation
guidelines could make ART unavailable to people with more advanced disease.110,111
Finally, adherence to ART started early might not be as reliable as treatment offered to
patients with more advanced disease.91
These important concerns lead to a counterpoint discussion. First, ART has unequivocal
public health benefit in prevention of HIV transmission at all CD4 cell counts.60 A
substantial proportion of people in Africa have shown high viral load throughout the course
of HIV infection (irrespective of CD4 cell count),84 so the public health benefits of ART
might be greatest in the epicentre of the pandemic. Second, although the extent to which
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people treated for HIV engage in risky behaviour is debated, HIV-infected people who are
treated are probably far less contagious than are those who are untreated.52,60,66–68
Parenthetically, perhaps a greater concern is the reported increase in risk behaviour of
people who are untested or untreated.74 Third, ongoing viral replication must be of some
consequence.113 With ongoing replication, CD4 cell count will fall and might not recover
quickly or completely.61,114 Increasing evidence suggests that ART reverses the T-cell
activation that favours replication and some markers of inflammation.5,115
Two randomised controlled trials of early initiation of ART, TEMPERANO
(NCT00495651) and START (NCT00867048), are in progress. However, randomised
controlled trials designed to compare the costs and benefits of ART started at high CD4 cell
counts (relative to a delay in therapy) are unlikely to last long enough to detect all the
clinical events associated with delayed ART or long-term side-effects of earlier ART, either
of which might not arise for decades.116 Finally, WHO guidelines suggest treatment of so
many people irrespective of CD4 cell counts (eg, HIV-infected people in discordant sexual
relationships, HIV-infected pregnant women, and perhaps people with acute HIV infection)
that the number of people who might logically defer ART will continue to decrease, making
the argument of the best time to start ART less relevant.
The logistical challenges needed to properly provide optimised treatment with earlier ART
initiation are important and real.111 If safe, well tolerated antiretroviral drugs are not
available, early treatment is far less likely to offer health benefit, and should be deferred.
Similarly, if so little infrastructure is available that therapy cannot be monitored or
sustained, early treatment makes little sense. But at the same time, logistical challenges must
not prevent development of the best available medical care, or in this case the best use of
medicine for public health. Logistical challenges will certainly slow ART rollout, but they
should not be used as a reason to abandon the desire to treat more people, or to treat them
sooner in the course of the disease.
Conclusion
ART, as a key component of combination prevention, has galvanised the call for an AIDS-
free generation.11 In this Review we have provided the rationale for the development of
treatment as prevention, described population-level evidence suggesting a chance for
success with this approach, and outlined four community randomised trials designed to
measure the population-level benefit from earlier or immediate ART. We have also stressed
the many limitations and challenges of implementation of treatment as prevention to
emphasise that sustained, population-level prevention benefit from earlier and wider use of
ART is not guaranteed. Where do we go from here? The observational measurements tied to
ART roll-out, and the large community trials in progress will inform estimates of HIV
incidence under various circumstances for treatment as prevention, as well as HIV
resistance, and population-level behaviour change. We hope to witness success in these
studies, and to gain critical information to inform improved treatment as prevention and
combination prevention approaches.
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• Treatment of an HIV-infected person will greatly reduce the probability of an
HIV transmission event
• Treatment as prevention requires careful attention to the best drug combinations
for clinical and public health benefit
• For treatment to affect the epidemic, improved detection of infection at all
stages, universal access to antiretroviral therapy (ART), and excellent adherence
are essential
• Treatment as prevention demands a robust health-care infrastructure
• Ongoing community-based randomised controlled trials of early ART are
measuring population-level benefit of treatment as prevention
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Search strategy and selection criteria
We searched PubMed and PsycInfo databases from Jan 1, 1990, to Aug 31, 2013, with
the terms: (“HIV” OR “AIDS”) AND (“antiretroviral” OR “ART” OR “ARV”) AND
(“treatment as prevention” OR “TasP” OR “prevent transmission”); and (“HIV” OR
“AIDS”) AND (“treatment” OR “antiretroviral” OR “ART” OR “ARV”) AND
(“discordant” OR “serodiscordant”) AND (“couples” OR “partners” OR “relationships”).
We used no other inclusion or exclusion criteria.
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Figure 1. Four opportunities for HIV prevention
The four stages of infection risk are listed at the top of the figure. Potential interventions
during each stage are listed within each box. The timeline for the intervention is listed in the
arrows below the intervention boxes. STD = sexually transmitted diseases. ART =
antiretroviral therapy. PrEP = pre-exposure prophylaxis. TDF/FTC = tenofovir disoproxil
fumarate co-formulated with emtricitabine (Truvada; Gilead Sciences, Foster City, CA,
USA). PEP=post-exposure prophylaxis. *TDF/FTC (Truvada) is the only ART intervention
currently approved by the US Food and Drug Administration for PrEP.
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Figure 2. Comparison of antiretroviral exposure at mucosal surfaces
Seminal plasma, cervicovaginal fluid, and colorectal tissue exposure is plotted as a ratio
relative to matched blood plasma exposure. The Y axis is on a log scale. Y = 1 is the line of
unity, at which mucosal surface exposure is similar to blood plasma. Total (protein free plus
protein bound) drug concentrations were used to calculate these ratios. Ratios above the line
of unity signify that drugs are concentrating at mucosal surfaces, whereas ratios below the
line of unity suggest that drug concentrations are lower than blood plasma at mucosal
surfaces. Semen concentration ratios are shown in white, cervicovaginal fluid in grey, and
rectal tissue in blue. MRV = maraviroc. RAL = raltegravir. DTG = dolutegravir. ETR =
etravirine. EFV = efavirenz. NVP = nevirapine. DLV = delavirdine. TFV = tenofovir. FTC =
emtricitabine. 3TC = lamivudine. ZDV = zidovudine. ABC = abacavir. DDI = didanosine.
D4T = stavudine. RTV = ritonavir. DRV = darunavir. IDV = indinavir. APV = amprenavir.
ATV = atazanavir. LPV = lopinavir. NFV = nelfinavir. SQV = saquinavir. ND = not
detected. Figure adapted from reference 40.
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